Clinical trials: Inflammatory Dermatoses
Psoriasis, Plaque Psoriasis
A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis
This is a double-blind, multicenter, vehicle-controlled, parallel group comparison study to determine and compare the efficacy and safety of HBP Lotion 0.05% and Vehicle Lotion applied twice daily for two weeks in subjects with…
- Trial name
- NCT01610596
- Testing
- Halobetasol Propionate Lotion 0.05%
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Therapeutics, Inc.
Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS)
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular…
- Conditions
- Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome (SS), Systemic Sclerosis (SSc), Inflammatory Myopathy
- Trial name
- in vivo CAR-T (NCT07413341)
- Testing
- TI-0032-III injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Therorna
Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects
CM-101 is developed as treatment for medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC), Systemic Sclerosis (SSc)
- Trial name
- NCT06037577
- Testing
- CM-101
- Where
- Israel
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- ChemomAb Ltd.
Rosacea
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular…
- Trial name
- NCT01308619
- Testing
- Doxycycline
- Where
- 10 sites in United States
- Volunteers
- 170 people
- Sponsor
- Galderma R&D
Acne Vulgaris
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris
This is a 91-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe acne vulgaris. Ten (10) subjects will receive RA-18C3 via subcutaneous injection.
- Trial name
- NCT01474798
- Testing
- RA-18C3
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Pharmacokinetics, Safety Issues
A Clinical Study With Adalimumab Biosimilar
The study aims to evaluate the pharmacokinetic profile, safety profile, and immunogenic potential of adalimumab of a new citrate-free formulation of adalimumab (Adalimumab Richmond) [Test Product] vs.
- Trial name
- NCT06291948
- Testing
- Humira® (adalimumab) AC Pen [Reference Product], Adalimumab Richmond [Test Product]
- Where
- Argentina
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Laboratorios Richmond S.A.C.I.F.
Psoriasis, Colitis, Ulcerative
A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically
The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the…
- Conditions
- Psoriasis, Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic
- Trial name
- NCT07654751
- Testing
- Breast Milk Sample Collection, Guselkumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.
- Trial name
- PALACE4 (NCT01307423)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 529 people
- Sponsor
- Amgen
Acne Vulgaris
Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel
This is a multi center open label study intended to provide photo documentation and time to response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to severe non-nodular inflammatory acne vulgarism.
- Trial name
- NCT02946788
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- BioPharmX, Inc.
Rosacea
Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea
The purpose of this study is to compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of inflammatory lesions rosacea
- Trial name
- NCT02795117
- Testing
- Ivermectin, Ivermectin (reference)
- Volunteers
- 486 people
- Sponsor
- Padagis LLC
Healthy, Psoriasis
Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg
The proposed exploratory study aims to understand the in vivo skin distribution properties of subcutaneously (s.c.) administered AIN457 in psoriatic and healthy skin using open flow microperfusion (OFM).
- Trial name
- OFM ISF (NCT01539213)
- Testing
- secukinumab (AIN457)
- Where
- Austria
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Acne, Post-inflammatory Hyperpigmentation
Clinical Efficacy of the Product in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP) Subjects
Double-blind, randomized, clinical study is designed to evaluate the efficacy of Niacinamide A in the management of facial Post Inflammatory Hyper Pigmentation (PIHP) in healthy female and male subjects with moderate to severe…
- Trial name
- NCT06822335
- Where
- Mauritius
- Volunteers
- 65 people
- Sponsor
- Cosmetique Active International
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Skin Condition
Fermented Grape Combined With Fruits and Vegetables Drink on Anti-aging and Anti-inflammatory
60 subjects were recruited and divided into placebo group and fermented grape drinks group.
- Trial name
- NCT04805697
- Testing
- fermented grape drinks
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- TCI Co., Ltd.
Acne
Evaluation of Effaclar Duo+M on Acne Lesions in Subjects With Mild to Moderate Acne on Face and Trunk
This single-center, open, non-randomized study aims the efficacy evaluation of Effaclar Duo+M and Effaclar+M Purifying foaming gel on total acne lesion count, pigmented lesions and scars for 6 months in subjects with mild to…
- Trial name
- NCT06463925
- Testing
- acneic participants group
- Where
- Brazil
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Hidradenitis Suppurativa
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
- Trial name
- Regulate-HS (NCT06361836)
- Testing
- SBT777101
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sonoma Biotherapeutics, Inc.
Inflammation, Skin Abnormalities
Effects of Bend Beauty's Anti-Aging Formula on Inflammatory Markers
This is a phase IV, randomized, double-blind, placebo-controlled, three-arm, parallel intervention study including three groups of 25 subjects between 35-65 years of age, treated with either Bend Beauty's Anti-Aging Formula, fish…
- Conditions
- Inflammation, Skin Abnormalities, Skin Pigment, Inflammatory Response
- Trial name
- BENCHMARK (NCT03862872)
- Testing
- Anti-Aging Formula, Control Fish Oil
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bend Beauty Inc.
Hidradenitis Suppurativa
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.
- Trial name
- NCT07007637
- Testing
- Sonelokimab
- Where
- 166 sites in United States, Belgium and 14 more
- Volunteers
- 835 people
- Sponsor
- MoonLake Immunotherapeutics AG
Advanced Solid Tumors, Breast Cancer
Dose-escalation Study of Oral CX-4945
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.
- Conditions
- Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease
- Trial name
- NCT00891280
- Testing
- CX-4945 oral formulation
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cylene Pharmaceuticals